Abstract
Disodium-4-chloro-2, 2'-iminodibenzoate, lobenzarit disodium (CCA) is an antirheumatic drug which was developed in Japan, and its effectiveness on patients with rehumatoid arthritis (RA) was confirmed.It is known that the acting mechanisms of conventionally used antirheumatic drugs to regulate human immunological abnormalities are caused by the macrophage inhibitory action of gold preparations and the inhibitory action of D-penicillamine on helper T-cells. How a new antirheumatic drug acts on the normalization against the immunological abnormalities of RA patients is a rheumatologically important problem. From the above point of view, we investigated the action of CCA on peripheral blood mononuclear cells to compare with those of gold and D-penicillamine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
